Related Experiment Video

Updated: Dec 7, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K

A Microbiota-Derived Metabolite Augments Cancer Immunotherapy Responses in Mice

Emma Allen-Vercoe1, Bryan Coburn2

  • 1Department of Molecular and Cellular Biology, University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada.

Cancer Cell
|September 25, 2020
PubMed

Insights

Certain gut microbes may enhance patient response to immune checkpoint blockade therapy. This research identifies a potential key molecule from the gut microbiome to improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Microbiome Research
  • Immunotherapy

Background:

  • Immune checkpoint blockade (ICB) therapy is a cornerstone of modern cancer treatment.
  • However, a significant proportion of patients do not respond to ICB therapy, necessitating strategies to improve response rates.

Purpose of the Study:

  • To investigate the role of the gut microbiome in modulating patient responses to ICB therapy.
  • To identify specific microbial factors that can enhance the efficacy of ICB treatment.

Main Methods:

  • Analysis of patient data and gut microbiome composition.
  • Identification and characterization of key molecules produced by specific gut bacteria.

Main Results:

  • Specific gut microbiome members were found to be associated with improved ICB therapy response.
  • A key molecule produced by these microbes was identified as a potential mediator of enhanced anti-tumor immunity.

Conclusions:

  • The gut microbiome plays a crucial role in determining patient response to ICB therapy.
  • Targeting specific gut microbial components represents a promising strategy to improve cancer immunotherapy outcomes.

More Related Videos

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System07:32

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System

Published on: August 30, 2019

9.1K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.4K